• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

验证一个包含牛津分类的国际预测模型在韩国 IgA 肾病患者中的应用。

Validation of an international prediction model including the Oxford classification in Korean patients with IgA nephropathy.

机构信息

Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, South Korea.

Division of Nephrology, Soonchunhyang University Cheonan Hospital, Chungcheongnam-do, South Korea.

出版信息

Nephrology (Carlton). 2021 Jul;26(7):594-602. doi: 10.1111/nep.13865. Epub 2021 Mar 3.

DOI:10.1111/nep.13865
PMID:33624915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8248408/
Abstract

BACKGROUND

Recently, a new international risk prediction model including the Oxford classification was published which was validated in a large multi-ethnic cohort. Therefore, we aimed to validate this risk prediction model in Korean patients with IgA nephropathy.

METHODS

This retrospective cohort study was conducted with 545 patients who diagnosed IgA nephropathy with renal biopsy in three medical centers. The primary outcome was defined as a reduction in estimated glomerular filtration rate (eGFR) of >50% or incident end-stage renal disease (ESRD). Continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI) were used to validate models.

RESULTS

During the median 3.6 years of follow-up period, 53 (9.7%) renal events occurred. In multivariable Cox regression model, M1 (hazard ratio [HR], 2.22; 95% confidence interval [CI], 1.02-4.82; p = .043), T1 (HR, 2.98; 95% CI, 1.39-6.39; p = .005) and T2 (HR, 4.80; 95% CI, 2.06-11.18; p < .001) lesions were associated with increased risk of renal outcome. When applied the international prediction model, the area under curve (AUC) for 5-year risk of renal outcome was 0.69, which was lower than previous validation and internally derived models. Moreover, cNRI and IDI analyses showed that discrimination and reclassification performance of the international model was inferior to the internally derived models.

CONCLUSION

The international risk prediction model for IgA nephropathy showed not as good performance in Korean patients as previous validation in other ethnic group. Further validation of risk prediction model is needed for Korean patients with IgA nephropathy.

摘要

背景

最近,一个包含牛津分类的新的国际风险预测模型已经发表,并在一个大型多民族队列中得到验证。因此,我们旨在验证该风险预测模型在韩国 IgA 肾病患者中的应用。

方法

本回顾性队列研究纳入了在三个医学中心接受肾活检诊断为 IgA 肾病的 545 名患者。主要结局定义为估算肾小球滤过率(eGFR)下降>50%或发生终末期肾病(ESRD)。连续净重新分类改善(cNRI)和综合判别改善(IDI)用于验证模型。

结果

在中位 3.6 年的随访期间,发生了 53 例(9.7%)肾脏事件。在多变量 Cox 回归模型中,M1(风险比[HR],2.22;95%置信区间[CI],1.02-4.82;p=0.043)、T1(HR,2.98;95%CI,1.39-6.39;p=0.005)和 T2(HR,4.80;95%CI,2.06-11.18;p<0.001)病变与肾脏结局风险增加相关。当应用国际预测模型时,5 年肾脏结局风险的曲线下面积(AUC)为 0.69,低于之前的验证和内部推导模型。此外,cNRI 和 IDI 分析表明,国际模型的区分度和重新分类性能逊于内部推导模型。

结论

国际 IgA 肾病风险预测模型在韩国患者中的表现不如其他种族群体的先前验证结果,需要进一步验证该模型在韩国 IgA 肾病患者中的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/87207b1f7bb0/NEP-26-594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/16d457ed6ecf/NEP-26-594-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/b169b09b2d24/NEP-26-594-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/87207b1f7bb0/NEP-26-594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/16d457ed6ecf/NEP-26-594-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/b169b09b2d24/NEP-26-594-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffef/8248408/87207b1f7bb0/NEP-26-594-g001.jpg

相似文献

1
Validation of an international prediction model including the Oxford classification in Korean patients with IgA nephropathy.验证一个包含牛津分类的国际预测模型在韩国 IgA 肾病患者中的应用。
Nephrology (Carlton). 2021 Jul;26(7):594-602. doi: 10.1111/nep.13865. Epub 2021 Mar 3.
2
Development and validation of a prediction rule using the Oxford classification in IgA nephropathy.应用牛津分类法在 IgA 肾病中建立并验证预测规则。
Clin J Am Soc Nephrol. 2013 Dec;8(12):2082-90. doi: 10.2215/CJN.03480413. Epub 2013 Oct 31.
3
External Validation of the International IgA Nephropathy Prediction Tool.国际 IgA 肾病预测工具的外部验证。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1112-1120. doi: 10.2215/CJN.16021219. Epub 2020 Jul 2.
4
Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.IgA 肾病患者的肾衰竭风险预测方程:一项中国患者的多中心风险评估研究。
Am J Kidney Dis. 2018 Sep;72(3):371-380. doi: 10.1053/j.ajkd.2018.01.043. Epub 2018 Mar 17.
5
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.评估 IgA 肾病的新型国际风险预测工具。
JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
6
External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients.老年患者中国际 IgA 肾病预测工具的外部验证。
Clin Interv Aging. 2024 May 21;19:911-922. doi: 10.2147/CIA.S455115. eCollection 2024.
7
Clinical Significance of Crescent Formation in IgA Nephropathy - a Multicenter Validation Study.IgA肾病中新月体形成的临床意义——一项多中心验证研究
Kidney Blood Press Res. 2019;44(1):22-32. doi: 10.1159/000497808. Epub 2019 Feb 22.
8
The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.牛津分类法在儿童 IgA 肾病中的应用与肾脏结局的相关性分析——一项回顾性队列研究。
BMC Nephrol. 2020 Jul 1;21(1):247. doi: 10.1186/s12882-020-01913-7.
9
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.IgA 肾病的病理评分是否具有长期价值?牛津 IgA 肾病分类(VALIGA)更新的验证研究。
Nephrol Dial Transplant. 2020 Jun 1;35(6):1002-1009. doi: 10.1093/ndt/gfy302.
10
Renal Interstitial Inflammation Predicts Nephropathy Progression in IgA Nephropathy: A Two-Center Cohort Study.肾间质炎症可预测IgA肾病的肾病进展:一项两中心队列研究
Am J Nephrol. 2022;53(6):455-469. doi: 10.1159/000524585. Epub 2022 May 16.

引用本文的文献

1
Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review.多病症和虚弱在肾衰竭预后预测模型的开发和验证中的表现:系统评价。
BMC Med. 2024 Oct 11;22(1):452. doi: 10.1186/s12916-024-03649-9.
2
Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.基于机器学习的IgA肾病诊断与预后:一项系统评价与荟萃分析。
Heliyon. 2024 Jun 14;10(12):e33090. doi: 10.1016/j.heliyon.2024.e33090. eCollection 2024 Jun 30.
3
Clinicopathological prognostic stratification for proteinuria and kidney survival in IgA nephropathy: a Japanese prospective cohort study.

本文引用的文献

1
External Validation of the International IgA Nephropathy Prediction Tool.国际 IgA 肾病预测工具的外部验证。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1112-1120. doi: 10.2215/CJN.16021219. Epub 2020 Jul 2.
2
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.评估 IgA 肾病的新型国际风险预测工具。
JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
3
Is immunoglobulin A nephropathy different in different ethnic populations?免疫球蛋白 A 肾病在不同种族人群中是否存在差异?
IgA肾病蛋白尿与肾脏生存的临床病理预后分层:一项日本前瞻性队列研究
Clin Kidney J. 2023 Nov 27;17(1):sfad294. doi: 10.1093/ckj/sfad294. eCollection 2024 Jan.
4
Learning more from the inter-rater reliability of interstitial fibrosis assessment beyond just a statistic.从间质纤维化评估的组内可靠性中学习到的不仅仅是统计学。
Sci Rep. 2023 Aug 15;13(1):13260. doi: 10.1038/s41598-023-40221-6.
5
Crescents and IgA Nephropathy: A Delicate Marriage.新月体与IgA肾病:一段微妙的关系
J Clin Med. 2022 Jun 21;11(13):3569. doi: 10.3390/jcm11133569.
6
The International IgA Nephropathy Network Prediction Tool Underestimates Disease Progression in Indian Patients.国际IgA肾病网络预测工具低估了印度患者的疾病进展。
Kidney Int Rep. 2022 Mar 24;7(6):1210-1218. doi: 10.1016/j.ekir.2022.03.016. eCollection 2022 Jun.
Nephrology (Carlton). 2019 Sep;24(9):885-895. doi: 10.1111/nep.13592. Epub 2019 May 1.
4
Clinical Significance of Crescent Formation in IgA Nephropathy - a Multicenter Validation Study.IgA肾病中新月体形成的临床意义——一项多中心验证研究
Kidney Blood Press Res. 2019;44(1):22-32. doi: 10.1159/000497808. Epub 2019 Feb 22.
5
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.肾小球疾病的管理和治疗(第 1 部分):来自肾脏病:改善全球预后(KDIGO)争议会议的结论。
Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.
6
Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.IgA 肾病牛津分类的可重复性、活检评分对治疗分配的影响以及分歧的临床意义:来自 VALIDATION 研究队列的证据。
Nephrol Dial Transplant. 2019 Oct 1;34(10):1681-1690. doi: 10.1093/ndt/gfy337.
7
A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity.一种基于临床和组织学严重程度组合来预测IgA肾病患者透析诱导风险的分级系统。
Clin Exp Nephrol. 2019 Jan;23(1):16-25. doi: 10.1007/s10157-018-1657-0. Epub 2018 Oct 26.
8
Genetic Determinants of IgA Nephropathy: Eastern Perspective.IgA 肾病的遗传决定因素:东方观点。
Semin Nephrol. 2018 Sep;38(5):455-460. doi: 10.1016/j.semnephrol.2018.05.015.
9
Epidemiology of IgA Nephropathy: A Global Perspective.IgA 肾病的流行病学:全球视角。
Semin Nephrol. 2018 Sep;38(5):435-442. doi: 10.1016/j.semnephrol.2018.05.013.
10
An update on predicting renal progression in IgA nephropathy.IgA 肾病中预测肾功能进展的研究进展。
Curr Opin Nephrol Hypertens. 2018 May;27(3):214-220. doi: 10.1097/MNH.0000000000000405.